Cynata chief operating officer Dr Kilian Kelly said, “The overall conclusion of the study is that Cymerus MSCs are highly consistent and that the Cymerus manufacturing process successfully bypasses much of the inherent variability that affects tissue-derived MSCs." …
Cynata announces presentation of data demonstrating consistency of its MSCs
November 16, 2022 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - - Latest News -
BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia
November 17, 2025 - - Latest News -
Syntara secures positive European opinion for orphan designation of amsulostat in myelofibrosis
November 17, 2025 - - Australian Biotech -
Mesoblast appoints Chief Financial Officer as it evolves into fully integrated commercial organisation
November 17, 2025 - - Australian Biotech -
Argent BioPharma secures significant financing facility to support strategic expansion
November 17, 2025 - - Australian Biotech -
Race Oncology launches new clinical programs in AML and lung cancer
November 17, 2025 - - Australian Biotech -
Noxopharm begins daily dosing in second phase of HERACLES trial
November 17, 2025 - - Australian Biotech